Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.

Ji, Lanlan; Gao, Dai; Hao, Yanjie; Huang, Hong; Wang, Yu; Deng, Xuerong; Geng, Yan; Zhang, Zhuoli

Ji, Lanlan; Gao, Dai; Hao, Yanjie; Huang, Hong; Wang, Yu; Deng, Xuerong; Geng, Yan; Zhang, Zhuoli.

Afiliação

Ji L; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Gao D; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Hao Y; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Huang H; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Wang Y; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Deng X; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Geng Y; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
Zhang Z; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.

Rheumatology (Oxford) ; 62(1): 181-189, 2022 12 23.

Article em En | MEDLINE | ID: mdl-35412598

Assuntos

Glucocorticoides; Lúpus Eritematoso Sistêmico; Humanos; Adulto; Glucocorticoides/efeitos adversos; Objetivos; Lúpus Eritematoso Sistêmico/tratamento farmacológico; Hidroxicloroquina/uso terapêutico; Prednisona/uso terapêutico

Palavras-chave

SLE; flare; glucocorticoid; predictors; withdrawal

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glucocorticoides / Lúpus Eritematoso Sistêmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google